MedTrace Logo

rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease

NCT02702518 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2021-09-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the tolerability and preliminary efficacy of rhDNase I eye drops in patients with ocular Graft-vs.-Host disease (oGVHD).

Conditions

  • Ocular Graft vs Host Disease
  • Dry Eye

Interventions

DRUG

rhDNase I

rhDNase I, 0.1% eye drops 4 times a day for 8 weeks

DRUG

Vehicle

Drug vehicle 4 times a day for 8 weeks

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • National Eye Institute (NEI)

    collaborator NIH

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Sandeep Jain, MD · University of Illinois at Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2020-04-08
Completion
2020-04-08

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02702518 on ClinicalTrials.gov